The statin-induced reduction of the two inflammatory markers was much more prominent for CHI3L1 than CRP, indicating difference between the two biomarkers in relation to their ability to monitor the inflammatory response in patients with IHD. This evidence concerns the gene CHI3L1 and myocardial ischemia.